+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening for germline EGFR T790M mutations through lung cancer genotyping

Screening for germline EGFR T790M mutations through lung cancer genotyping

Journal of Thoracic Oncology 7(6): 1049-1052

The study of patients carrying germline epidermal [corrected] growth factor receptor (EGFR) mutations, which have been found in cases of familial lung adenocarcinoma, could provide unique insight into lung cancer risk and carcinogenesis in never-smokers. However, investigations into the biology of germline EGFR mutations have been hampered by the lack of an effective strategy for screening for carriers. We hypothesized that patients with lung cancers found to harbor the EGFR T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline T790M mutations. Eleven unrelated patients with lung cancer, harboring an EGFR T790M mutation, were identified from a 7-year institutional experience with tumor genotyping. Ten patients had benign tissue available, which was anonymously tested for the presence of germline EGFR mutations. Five of 10 cases carried a germline T790M mutation (50%, confidence interval 27%-73%). One patient's cancer exhibited a distinctive indolent growth, which has also been described in preclinical studies of T790M-mutant cancers. A second patient underwent resection of six separate primary lung adenocarcinomas, each carrying different sensitizing EGFR mutations and T790M. Genotyping of lung cancers, now commonly performed to predict benefit from treatment with EGFR tyrosine kinase inhibitors, can also be used as a screening tool to identify patients at risk of carrying germline EGFR mutations. Once identified, these patients and their families can be studied prospectively to explore appropriate lung cancer screening strategies. Further studies using existing oncogenomic data to provide insight into underlying germline genetics are warranted.

(PDF emailed within 0-6 h: $19.90)

Accession: 055671750

Download citation: RISBibTeXText

PMID: 22588155

DOI: 10.1097/JTO.0b013e318250ed9d

Related references

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. Journal of the National Comprehensive Cancer Network 12(1): 6-11; Quiz 11, 2014

Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. Journal of Thoracic Oncology 9(4): 456-463, 2015

EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing. Journal of the National Comprehensive Cancer Network 15(10): 1188-1192, 2018

MA 15.08 Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation. Journal of Thoracic Oncology 12(11): S1863-S1864, 2017

Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer 17(2): E5-11, 2016

EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR. Oncotarget 9(100): 37393-37406, 2019

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. Bmc Cancer 18(1): 1241-1241, 2018

Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology. Pathology, Research and Practice: -, 2018

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clinical Cancer Research 23(23): 7351-7359, 2017

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discovery 4(9): 1036-1045, 2016

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer. Molecular Cancer Therapeutics 16(11): 2563-2571, 2017

Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. Oncotargets and Therapy 11: 3335-3343, 2018

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clinical Cancer Research 17(5): 1160-1168, 2011

Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. Lung Cancer 108: 75-82, 2018

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73(1): 96-102, 2011